Cell Therapy Developer Rubius Therapeutics Raises $100M More

Rubius Therapeutics said today it has raised $100 million in new financing to further support clinical development and manufacturing of its new red blood cell–derived therapies.The oversubscribed $100 million “crossover” financing brings to more than $220 million the amount of capital raised by the company. In June, Rubius closed on $120 million in a private financing round it said at the time was “highly oversubscribed.”Rubius said proceeds from the financing will